凯信远达上涨4.03%，报2.455美元/股，总市值3803.45万美元

Core Insights - CASI Pharmaceuticals (凯信远达) experienced a stock price increase of 4.03% on August 25, reaching $2.455 per share, with a total market capitalization of $38.0345 million [1] - For the fiscal year ending March 31, 2025, CASI reported total revenue of $6.24 million, reflecting an 83.04% year-over-year growth, while the net profit attributable to shareholders was -$10.75 million, a decrease of 12.83% year-over-year [1] Company Overview - CASI Pharmaceuticals is a Nasdaq-listed biopharmaceutical company based in Rockville, Maryland, USA, focused on providing advanced treatment solutions for blood cancers in Chinese patients [2] - The company has a wholly-owned subsidiary in Beijing and joint ventures and research centers in Wuxi with local government [2] - CASI's product and research pipeline covers multiple disease areas, including multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [2]